Sarepta under pressure as competitor files with FDA for Duchenne drug

Sarepta under pressure as competitor files with FDA for Duchenne drug

STAT Plus: Sarepta under new pressure as a competitor files with FDA for Duchenne drug

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

If approved, the NS Pharma drug would be the first treatment for children born with Duchenne caused by a mutation in the DNA sequence known as exon 53.

READ MORE